about
Non-steroid agents for idiopathic pulmonary fibrosisRifabutin for treating pulmonary tuberculosisLevels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments.Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice.Human mucosal associated invariant T cells detect bacterially infected cells.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosisCorticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis.Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report.Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature.Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review.Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature.The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays.Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective studyInterstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients.Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis.Ultrasound-assessed diaphragmatic impairment is a predictor of outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease undergoing noninvasive ventilation.Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis."Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cellsA Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary FibrosisThe encaged lung: rapidly progressive idiopathic pleurisyPerformance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised PatientsUsing ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TBassayPulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary FibrosisEmerging drugs for idiopathic pulmonary fibrosisGenetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning?Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device).Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature.Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung DiseaseThe prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidoneClinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysisJanus-faced amiodarone-induced pneumopathyDo Not Forget to Assess the Muscle Integrity in Patients With COPD
P50
Q24235478-494A23C2-F2F2-4237-92C3-50CC593EB87CQ24242892-E68079DD-83B9-4995-A5BC-283823ADE7A7Q30398970-D7808F40-AC1D-4176-805E-005AA87CFE13Q33598903-09FF91DA-3279-4810-9388-C7804871697CQ33627502-1F4312BF-EC6F-4983-8C0F-13973B7B2DAAQ34061748-C700A76C-DE98-4849-8F9A-1B24BE241589Q34299791-27A9ABB6-B90E-4EF2-A91E-98B40C958D18Q35939413-2B05F6DD-9DC5-49D9-B4B5-FFD1615A5671Q37076998-7F6826AE-E008-48BD-805D-4AA7A0B25792Q38022370-613F219B-7E2B-4344-8C05-C8ED1A03B423Q38352111-AECABE2D-7849-4628-9F36-3AA66F73A318Q38589045-74B7547E-4C34-41B1-BA6F-D961B84C6F4FQ38787176-A992645F-D3E9-41D5-8763-F20689A9F5A3Q40660539-1FADA680-B0CF-4013-ABE0-CB33FA1FB945Q41746404-3F05D31E-96BD-4DE7-B6D4-16BEB2B254C4Q42373513-41E3BF97-3FB3-490D-9BE5-D3A3E5F4947CQ44545617-0905B2EC-57F8-4D7E-8415-87E3F9F757C2Q47943833-3D43CE67-DCC1-4CCB-9FB8-563378078962Q50048611-71D4CCE9-5CE9-4135-8300-F5BBC12564A0Q51066323-D0787471-D735-4B1B-84AC-F6A0DFDD50D1Q52642363-D9373CC7-22B7-4831-919A-1E78ECADDF26Q52650597-C36F9B1A-67AB-456B-A110-F0509812EA5AQ55002085-C5664880-3A95-4C61-B86A-04FEA5637336Q55009120-64B310DD-9852-41B6-A862-E963A0955992Q55330140-8AEE8381-C842-4633-8DDC-3383AFA038F2Q57195195-2E2F24D6-0621-4EDA-AD34-3038DEA4B6F2Q57786474-FFA7ACA1-26A4-4DAF-878A-EF592C03DDFAQ58794521-BF442709-8A07-4A39-9EA3-6FCF8FA2AFE8Q58877097-393492F1-4E4D-4FFA-BBBD-584C3F3931A9Q58877140-5CC44F96-8C69-467E-AF7A-BFE583087B88Q58895800-6333D067-E22F-487C-BE28-20C41F432F1EQ58895811-7C1871C2-94C1-4B18-AD72-24545C36409CQ58895813-1CBC0EFB-F5EF-41F2-B0A6-210D68E9AE31Q64881839-775737E8-0848-4900-BEC0-4621CA31FB4FQ64898820-5DE2EC00-2781-4BE7-8EE2-F88BD481539DQ90779570-2E361313-18BE-4F75-AA1A-6ABD20AF217FQ91191004-5AAAB070-8FB0-4EB0-A608-838CBA20A36EQ92184947-39EEBA79-BBD2-45CF-8421-77253607A89AQ92459018-200FC832-F92B-438A-8F0C-F04ABED96CB8Q92591497-4C4A4347-5E3A-4A4B-9209-1D52CCE4376F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Stefania Cerri
@ast
Stefania Cerri
@en
Stefania Cerri
@es
Stefania Cerri
@nl
Stefania Cerri
@sl
type
label
Stefania Cerri
@ast
Stefania Cerri
@en
Stefania Cerri
@es
Stefania Cerri
@nl
Stefania Cerri
@sl
prefLabel
Stefania Cerri
@ast
Stefania Cerri
@en
Stefania Cerri
@es
Stefania Cerri
@nl
Stefania Cerri
@sl
P214
P106
P1153
8580439400
P21
P214
P31
P396
IT\ICCU\CFIV\264991
P496
0000-0003-4612-1580
P569
1977-01-01T00:00:00Z
P735
P7859
viaf-307341274